You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

EGFR Positive

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

CNS Tumor, Pediatric, Glioma, Ependymoma Trial in Seattle (EGFR806-specific chimeric antigen receptor (CAR) T cell)

Active, not recruiting
  • Central Nervous System Tumor, Pediatric
  • +8 more
  • EGFR806-specific chimeric antigen receptor (CAR) T cell
  • Seattle, Washington
    Seattle Children's Hospital
Jan 18, 2023

Patients With Advanced EGFR Positive Non-Small Cell Lung Cancer

Recruiting
  • Lung Cancer Non-small Cell Stage IV
    • Athens, Greece
      Hellenic Cooperative Oncology Group
    Nov 14, 2022

    Advanced Solid Tumors Trial in Guangzhou, Changsha (MRG003+HX008)

    Recruiting
    • Advanced Solid Tumors
    • Guangzhou, Guangdong, China
    • +1 more
    Jan 15, 2023

    Non Squamous Non Small Cell Lung Cancer, EGFR Positive NSCLC Trial (Toripalimab plus Chemotherapy)

    Not yet recruiting
    • Non Squamous Non Small Cell Lung Cancer
    • EGFR Positive Non-small Cell Lung Cancer
    • Toripalimab plus Chemotherapy
    • (no location specified)
    Jul 28, 2023

    NSCLC, NSCLC Trial in Miami, Cleveland (Osimertinib)

    Active, not recruiting
    • NSCLC
    • Non-small Cell Lung Cancer
    • Miami, Florida
    • +1 more
    Nov 8, 2022

    Solid Tumor, Adult, EGFR Overexpression Trial in Beijing (TGFßR-KO CAR-EGFR T Cells)

    Recruiting
    • Solid Tumor, Adult
    • EGFR Overexpression
    • TGFβR-KO CAR-EGFR T Cells
    • Beijing, Beijing, China
      Chinese PLA General Hospital
    Mar 25, 2022

    Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in Duarte, New Haven (procedure, drug, radiation, other)

    Not yet recruiting
    • Lung Non-Small Cell Carcinoma
    • Stage IV Lung Cancer AJCC v8
    • Biospecimen Collection
    • +5 more
    • Duarte, California
    • +1 more
    Aug 24, 2023

    Advanced EGFR Positive Solid Tumor Trial in China, United States (ZZ06)

    Recruiting
    • Advanced EGFR Positive Solid Tumor
    • ZZ06
    • Los Angeles, California
    • +3 more
    Mar 7, 2022

    NSCLC Trial in Shanghai (IN10018, Furmonertinib)

    Recruiting
    • NSCLC
    • Shanghai, China
      Shanghai Pulmonary Hospital
    Aug 8, 2023

    Non Small Cell Lung Cancer, EGFR Gene Mutation, Immune Checkpoint Inhibitor Trial in Jerusalem (concomitant TTFields treatment

    Not yet recruiting
    • Non Small Cell Lung Cancer
    • +2 more
    • concomitant TTFields treatment device to standard of care EGFR positive NSCLC treatment
    • concomitant TTFields treatment device to standard of care anti PD-1 NSCLC treatment
    • Jerusalem, Israel
      Shaare Zedek Medical Center
    Jan 22, 2023

    Osimertinib for Advanced EGFR-positive NSCLC Patients

    Recruiting
    • EGFR Positive Non-small Cell Lung Cancer
    • Non Small Cell Lung Cancer
      • Singapore, Singapore
        National University Hospital
      Aug 31, 2021

      Lung Cancer, Non-small Cell, EGFR Gene Mutation, EGFR-TKI Resistant Mutation Trial in Changsha (Genomic profiles detection,

      Recruiting
      • Lung Cancer, Non-small Cell
      • +4 more
      • Genomic profiles detection
      • circulating tumor DNA detection
      • Changsha, Hunan, China
        Department of Oncology, The Second Xiangya Hospital, Central Sou
      Oct 25, 2022

      Lung Cancer, Colorectal Cancer Trial in Saskatoon (50 mg 89Zr-DFO-Nimotuzumab, 1 mg 89Zr-DFO-Nimotuzumab)

      Recruiting
      • Lung Cancer
      • Colorectal Cancer
      • 50 mg 89Zr-DFO-Nimotuzumab
      • 1 mg 89Zr-DFO-Nimotuzumab
      • Saskatoon, Saskatchewan, Canada
        Royal University Hospital
      May 18, 2022

      NSCLC, EGFR Sensitive Mutation, Adjuvant Therapy Trial in Beijing, Nanjing, Shanghai (Befotertinib + Icotinib , Icotinib +

      Recruiting
      • Non-Small Cell Lung Cancer
      • +2 more
      • Befotertinib + Icotinib placebo
      • Icotinib + Befotertinib placebo
      • Beijing, China
      • +2 more
      Sep 20, 2023

      NSCLC Trial (Almonertinib Envafolimab)

      Not yet recruiting
      • Non-small Cell Lung Cancer
      • Almonertinib Envafolimab
      • (no location specified)
      Sep 10, 2022

      NSCLC Stage III, EGFR Positive NSCLC, Non-squamous Non-small-cell Lung Cancer Trial in Korea, Republic of (Lazertinib)

      Recruiting
      • Non-small Cell Lung Cancer Stage III
      • +2 more
      • Busan, Korea, Republic of
      • +12 more
      Jan 17, 2023

      EGFR Positive NSCLC Trial in Goyang-Si (Erlotinib plus Bevacizumab, Erlotinib)

      Active, not recruiting
      • EGFR Positive Non-small Cell Lung Cancer
      • Goyang-Si, Gyeonggi-do, Korea, Republic of
        National Cancer Center
      Apr 4, 2022

      NSCLC Trial in Seoul (Lazertinib/Pemetrexed/Carboplatin)

      Not yet recruiting
      • Non-small Cell Lung Cancer
      • Seoul, Korea, Republic of
        Yonsei University Health System, Severance Hospital
      Mar 23, 2023

      Lung Cancer, TKI Resistance, EGFR Sensitive Mutation Trial (Anlotinib, Penpulimab)

      Not yet recruiting
      • Lung Cancer
      • +4 more
      • (no location specified)
      Sep 15, 2023

      Central Nervous System Metastatic EGFR Mutation Positive NSCLC

      Not yet recruiting
      • NSCLC
        • Changsha, Hunan, China
          Hunan Cancer hospital
        Aug 6, 2023

        NSCLC Stage IIIB, NSCLC Stage IIIC, NSCLC Stage IV Trial in Worldwide (Dacomitinib)

        Active, not recruiting
        • NSCLC Stage IIIB
        • +4 more
        • Hong Kong, Hong Kong
        • +8 more
        Jan 10, 2023

        NSCLC Trial in Shanghai (TY-9591(10mg,40mg) qd. po)

        Recruiting
        • NSCLC
        • TY-9591(10mg,40mg) qd. po
        • Shanghai, China
          Shanghai Chest Hospital
        Nov 7, 2021

        EGFR/ B7H3-positive Advanced Lung Cancer, EGFR/ B7H3-positive Advanced Triple-negative Breast Cancer Trial in Guangzhou

        Recruiting
        • EGFR/ B7H3-positive Advanced Lung Cancer
        • EGFR/ B7H3-positive Advanced Triple-negative Breast Cancer
        • EGFR/B7H3 CAR-T
        • Guangzhou, Guangdong, China
          Second Affiliated Hospital of Guangzhou Medical University
        Apr 18, 2022

        Lung Adenocarcinoma Stage III, Lung Adenocarcinoma Stage IV, EGFR Gene Mutation Trial in Shanghai (Furmonertinib, Bevacizumab)

        Recruiting
        • Lung Adenocarcinoma Stage III
        • +2 more
        • Shanghai, Shanghai, China
          Shanghai Pulmonary Hospital
        Aug 13, 2022

        Breast Cancer Trial in Switzerland (anti-EGFR-IL-dox)

        Terminated
        • Breast Cancer
        • Aarau, Switzerland
        • +14 more
        Sep 27, 2021